Taxane- and epothilone-based chemotherapy: From molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 12, 2013, Pages 1658-1664

  Alberti, Contardo ^a  

^a LD of Surgical Semeiotics   (Italy)

Author keywords

Androgen resistance; Cancer stem cells; Cytoskeletal logistics; Nanotechnology; Radiation therapy

Indexed keywords

CABAZITAXEL; CYTOCHALASIN D; DOCETAXEL; EPOTHILONE B; EPOTHILONE DERIVATIVE; GROWTH FACTOR RECEPTOR; IXABEPILONE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOXANTRONE; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; NOSCAPINE; PACLITAXEL; PERTENOTOXIN DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; SAGOPILONE; TANESPIMYCIN; TAXANE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG; VINCA ALKALOID;

ACTIN FILAMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL MEMBRANE; CYTOSKELETON; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HUMAN; MICROTUBULE; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; MITOSIS SPINDLE; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA; CASTRATION; CYTOSKELETON; EPOTHILONES; HUMANS; MALE; PROSTATIC NEOPLASMS; TAXOIDS; TUBULIN MODULATORS;

EID: 84884321808     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. JEMAL A, BRAY F, CENTER MM, FERLAY J, WARD E, FORMAN D. Global cancer statistics. Ca Cancer J Clin 2011; 61: 69-90.
2. VAN DER POEL HG. Smart drugs in prostate cancer. Eur Urol 2004; 45: 1-17.
3. VISHNU P, TAN WW. Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Target Ther 2010; 24: 39-51.
4. ALBIGES L, LORIOT Y, GROSS-GOUPIL M, DE LA MOTTE ROUGE T, BLESIUS A, ESCUDIER B, MASSARD C, FIZAZI K. New drugs in metastatic castration-resistant prostate cancer. Bull Cancer 2010; 97: 149-159.
5. WU Y, ROSENBERG JE, TAPLIN ME. Novel agents and new therapeutics in castration-resistant prostate cancer. Curr Opin Oncol 2011; 23: 290-296.
6. KIRBY RS, FITZPATRICK JM, CLARKE N. Abarelix and other Gn-RH antagonists in prostate cancer. BJU Int 2009; 104: 1580-1584.
7. SONESSON A, RASMUSSEN BB. In vitro studies investigation the interactions between Degarelix and Cytochrome P450. Basic Clin Pharmacol Toxicol 2011; 109: 195-202.
8. VASAITIS TS, NJAR VC. Novel potent anti-androgens of therapeutic potential: recent advances and developments. Future Med Chem 2010; 2: 667-680.
9. SCIARRA A, INNOCENZI M, RAVAZIOL M, MINISOLA F, ALFARONE A, CATTARINO S, MONTI G, GENTILE V, DI SILVERIO F. Neuroendocr ine target therapies for prostate cancer. Urologia 2011; 78: 137-141.
10. MASSARD C, FIZAKI T. Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 2011; 17: 3876-3883.
11. ATTARD G, REID AH, OLMOS D, DE BONO JS. Antitumor activity with CYP17 blockade indicates that CRPC frequently remains hormone driven. Cancer Res 2009; 15: 4937-4940.
12. SONPAVDE G, STERNBERG CN. Contemporary management of metastatic castration-resistant prostate cancer. Curr Opin Urol 2011; 21: 241-247.
13. KIM SJ, KIM I. Current treatment strategies for castration- resistant prostate cancer. Korean J Urol 2011; 52: 157-165.
14. ANSARI J, HUSSAIN SA, ALHASSO A, MAHMOOD R, ANSARI A, GLAH J. Role of second-line systemic treatment post-docetaxel in metastatic CRPC: current strategies and future directions. Anticancer Agents Med Chem 2011; 11: 296-306.
15. MAHMOUDIAN M, RAHIMI-MOGHODDAM P. The anticancer activity of noscapine: a review. Rec Pat Anticancer Drug Disc 2009; 4: 92-97.
16. FLEMING M, SONPAVDE G, KONDAGUNTA GV, GALSKY M, HUTSON TH E, STERNBERG CN. Systemic therapy and novel agents for metastatic castration-resistant prostate cancer. Update Cancer Ther 2009; 3: 133-145.
17. KIM MO, MOON DO, HEO MS, LEE JD, JUNG JH, KIM SK, CHOI YH, KIM GY. Pertenotoxin-2 abolishes activated NF-| B leading to suppression of NF-| B gene products and potentiation of apoptosis. Cancer Lett 2008; 271: 25-33.
18. ANTONARAKIS ES, CARDUCCI MA, EISENBERG MA. Novel targeted therapeutics for metastatic castration-resistant prostate cancer.Cancer Lett 2010; 291: 1-13.
19. ULLRICH A. Molecular targets in cancer therapy and their impact on cancer management. Oncology 2002; 63(Suppl 1): 1-5.
20. KYPRIANOU N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J Urol 2003; 169: 1520-1525.
21. SAKAMOTO S, SCHWARZE S, KYPRIANOU N. Anoikis disruption of focal adhesion-Akt signaling impairs renal cell carcinoma. Eur Urol 2011; 59: 734-744.
22. HORI Y, ISHII K, KANDA H, IWAMOTO Y, NISHIKAWA K, SOGA N, KISE H, ARIMA K, SUGIMURA Y. Naftodipil, a selective alpha 1- adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma. Cancer Prev Res 2011; 4: 87-96.
23. ALBERTI C. Apoptosis induction by quinazoline-derived alpha1-blockers in prostate cancer cells: biomolecular implications and clinical relevance. Eur Rev Med Pharmacol Sci 2007; 11: 59-64.
24. LEBRET T, MÉJEAN A, HOUÉDÉ N. Physiopathology and new therapeutic strategies in the management of bone metastases of prostate cancer. Progr Urol 2011; 21: 301-307.
25. ABDULLA A, KAPOOR A. Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Can Urol Assoc 2011; 5: 120-133.
26. NABHAN C, PARSONS B, TOULOUKIAN EZ, STADLER WM. Novel approaches and future directions in castration- resistant prostate cancer. Ann Oncol 2011; 22: 1948-1957.
27. CHEEVER MA, HIGANO C. PROVENGE (Sipuleucel- T) in prostate cancer: the first FDA approved therapeutic cancer vaccine. Clin Cancer Res 2011; 17: 3520-3526.
28. MAY KF, GRILLEY JL, DRAKE CH G, DRANOFF G, KANTOFF PW. Prostate cancer immunotherapy. Clin Cancer Res 2011; 17: 5233-5238.
29. MORI T. Ipilimumab, a new molecular targeted therapy of malignant neoplastic disease. Gan To Kagaku Ryoho 2011; 38: 31-35.
30. MADAM RA, PAL SK, SARTOR O, DAHUT WL. Overcoming chemotherapy resistance in prostate cancer. Clin Cancer Res 2011; 17: 3892-3901.
31. BANGMA CH, MONGIAT P, KRAAU R, SCHENK-BRAAT E. Gene therapy in urology: strategies to translate theory into practice. BJU Int 2005; 96: 1163-1170.
32. DE FOUGEROLLES A, VORNLOCHER HP, MARAGANORE J, LIEBNERMAN J. INTERFERING WITH DISEASE: A PROGRESS report siRNA-based therapeutics. Nat Rev Drug Discov 2007; 6: 443-453.
33. GRECO A, DI BENEDETTO A, HOWARD CM, KELLY S, NANDE R, DEMENTIEVA Y, MIRANDA M, BRUNETTI A, SALVATORE M, CLAUDIO L, SARKAR D, DENT P, CURIEL DT, FISHER PB, CLAUDIO PP. Eradication of therapy-resistant human prostate tumors using an ultrasoundguided site-specific cancer terminator virus-delivery approach. Mol Ther 2010; 18: 295-306.
34. HWANG JJ, KIM YS, KIM MJ, KIM DE, JEONG IG, KIM CS. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cells. J Urol 2010; 184: 2557-2564.
35. BAE KM, SU Z, FRYE C, MCCLELLAN S, ALLAN RW, ANDREJEWSKI JT, KELLEY V, JORGENSEN M, STEINDLER DA, VIEWEGT J, SIEMANN DW. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol 2010; 183: 2045-2053.
36. BISTOLFI F. The bioconductive connectional system. In: Bistolfi F. Biostructures and radiations: orderdisorder. Torino. Minerva Medica 1991; 53-60.
37. ROSS JL, ALI MY, WARSHAW DM. Cargo transport: molecular motors navigate a complex cytoskeleton. Curr Opin Cell Biol 2008; 20: 41-47.
38. GOLDMAN RD, GRIN B, MENDEZ MG, KUCZMARSKI ER. Intermediate filaments: versatile building blocks of cell structure. Curr Opin Cell Biol 2008; 20: 28-34.
39. MIACZYNSKA M, PELKMANS L, ZERIAL M. Not just a sink: endosomes in control of signal transduction. Curr Opin Cell Biol 2004; 16: 400-406.
40. WATANABE TM, HIGUCHI H. Stepwise movements in vesicle transport of HER-2 by motor proteins in living-cells. Biophys J 2007; 20: 4109-4120.
41. OWEN DJ. Linking endocytic cargo to clathrin: structural and functional insights into coated vesicle formation. Biochem Soc Trans 2004; 32: 1-14.
42. VAN MEER G, SPRONG H. Membrane lipids and vesicular traffic. Curr Opin Cell Biol 2004: 16: 373-378.
43. SETTEMBRE C, DI MALTA C, POLITO VA, ARENCIBIA MG, VETRINI F, ERDIN S, ERDIN SU, HUYNH T, MEDINA D, COLELLA P, SORDIELLO M, RUBINSZTEIN DC, BALLABIO A. TFEB links autophagy to lysosomal biogenesis. Science 2011; 332: 1429-1433.
44. POKORNY J, HASEK J, VANIS J, JELINEK F. Biophysical aspects of cancer-electromagnetic mechanism. Indian Exp Biol 2008; 46: 310-321.
45. YUE QX, LIU X, GUO DA. Microtubule-binding natural products for cancer therapy. Planta Med 2010; 76: 1037-1043.
46. ALBERTI C. Cytoskeleton structure and dynamic behaviour: quick excursus from basic molecular mechanisms to some implications in cancer chemotherapy. Eur Rev Med Pharmacol Sci 2009; 13: 13-21.
47. PASQUIER E, KAVALLARIS M. Microtubules: a dynamic target in cancer therapy. IUBMB Life 2008; 68: 165-170.
48. BHANDARY MS, HUSSAIN M. Epothilones and the new generation of phase 3 trials for prostate cancer. BJU Int 2005; 96: 296-302.
49. DE BONO JS, OUDARD S, OZGUROGLU M, HANSEN S, MACHIELS JP, KOCAK I, GRAVIS G, BODROGI I, MACKENZIE MJ, SHEN L, ROESSNER M, GUPTA S, SARTOR AO. Prednisone plus cabazitaxel or mitoxantrone for metastatic CRPC progressing after docetaxel treatment. Lancet 2010; 376: 1147-1154.
50. OUDARD S. TROPIC: phase 3 trial of cabazitaxel for treatment of metastatic castration-resistant prostate cancer. Future Oncol 2011; 7: 497-506.
51. BOUCHET BP, GALMARINI CM. Cabazitaxel, a new taxane with favorable properties. Drugs Today 2010; 46: 735-742.
52. ZHU ML, HORBINSKI CM, GARZOTTO M, QIAN DZ, BEER TM, KYPRIANOU N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 2010; 70: 7992-8002.
53. SOLIT DB, SCHER HI, ROSEN N.Hsp90 as therapeutic target in prostate cancer.Sem Oncol 2003; 30: 709-716.
54. ZHOU Q, CHING AK, LEUNG WK, SZETO CY, HO SM, CHAN PK, YUAN YF, LAI PB, YEO W, WONG N. Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma. Int J Oncol 2011; 38: 721-731.
55. KRATZ F. Albumin, a versatile carrier in oncology. Int J Clin Pharmacol Ther 2010; 48: 453-455.
56. KAMATH K, JORDAN MA. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. Cancer Res 2003; 63: 6026-6031.
57. GOODIN S, KANE MP, RUBIN EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004: 2015-2025.
58. MUHLRADT PF, SASSE F. Epothilone B stabilizes microtubuli of macrophages like taxol without showing taxol-like endotoxin activity. Cancer Res 1997; 57: 3344-3350.
59. GANGULY A, YANG H, CABRAL F. Paclitaxel-dependent cell lines reveal a novel drug activity. Mol Cancer Ther 2010; 9: 2914-2923.
60. BYSTRICKY B, CHAU I. Patupilone in cancer treatment. Expert Opin Investig Drugs 2011; 20: 107-117.
61. KOWALSKI RJ, GIANNAKAKON P, HAMEL E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel. J Biol Chem 1997; 272: 2534-2541.
62. JULIEN B, SHAH S. Heterologous expression of epithilone biosynthetic genes in Myxococcus xanthus. Antimicrob Agents Chemother 2002; 46: 2772-2778.
63. KONG Z, RAGHAVAN P, XIE D, BOIKE T, BURMA S, CHEN D, CHAKRABORTY A, HSIEH JT, SAHA D. Epothilone B confers radiation dose enhancement in DAB2IP gene knock-down radioresistant prostate cancer cells. Int J Radiat Biol Biophys 2010; 78: 1210-1218.
64. PANNU V, KARNA P, SAJJA HK, SHUKLA D, ANEJA R. Synergistic antimicrotubule therapy for prostate cancer. Biochem Pharmacol 2011; 81: 478-487.
65. CARLSON RO. New tubulin-targeting agents currently in clinical development. Expert Opin Investig Drugs 2008; 17: 707-722.
66. KIM M, LIAO J, DOWLING ML, VOONG KR, PARKER SE, WANG S, EL-DEIRY WS, KAO GD. TRAIL inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in human man cancer cells.Cancer Res 2008; 68: 3440-3449.
67. SINGH P, RATHINASAMI K, MOHAN R, PANDA D. Microtubule assembly and dynamics: an attractive target for anticancer drugs. IUBMB Life 2008; 60: 368-375.
68. ZIMMERMANN KG, BONZON C, GREEN OR. The machinery of programmed cell death. Pharmacol Ther 2001; 92: 57-70.
69. ROVINI A, SAVRI A, BRAGUER D, CARRÉ M. Microtubule- targeted agents: when mitochondria become essential to chemotherapy. Biochem Biophys Acta 2011; 1807: 679-688.
70. HARRISON M, SWANTON C. Epothilones and new analogues of microtubule modulators in taxaneresistant disease. Expert Opin Invest Drugs 2008; 17: 523-546.
71. DANILA M, FLEISHER M, SCHER HI. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011; 17: 3903-3912.
72. FERRARI M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005; 5: 161-171.
73. WICHA MS, HAYES DF. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol 2011; 29: 1508-1510.
74. EVANS AJ, RYAN P, VAN DERKWAST T. Treatment effects in the prostate including those associated with traditional and emerging therapies. Adv Anat Pathol 2011; 18: 281-293.
75. ATTARD G, DE BONO J. Translating scientific advancement into clinical benefit for CRPC patients. Clin Cancer Res 2011; 17: 3867-3875.